Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Looking for participantsNCT06552559
What this trial is testing

Selinexor With ICE Chemotherapy in Secondary Central Nervous System Involving B-cell Non-Hodgkin Lymphoma

Who this might be right for
B-cell Lymphoma RecurrentB-cell Lymphoma RefractoryCNS Metastases
Samsung Medical Center 37
Large-scale testing (Phase 3)Active Not RecruitingNCT05578976
What this trial is testing

Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined With Intravenous and Oral Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone (R-CHOP) or R-CHOP in Adult Participants With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)

Who this might be right for
Diffuse Large B-Cell Lymphoma
Genmab 900
Testing effectiveness (Phase 2)Study completedNCT02445248
What this trial is testing

Study of Efficacy and Safety of CTL019 in Adult DLBCL Patients

Who this might be right for
Diffuse Large B-cell Lymphoma (DLBCL)
Novartis Pharmaceuticals 115
Very early researchStudy completedNCT02405078
What this trial is testing

Tumor-Specific Clonotype, Metabolic Profile, and PET/CT in Predicting Chemotherapy Response in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma

Who this might be right for
Recurrent Diffuse Large B-Cell LymphomaRefractory Diffuse Large B-Cell Lymphoma
M.D. Anderson Cancer Center 35
Testing effectiveness (Phase 2)WithdrawnNCT04285268
What this trial is testing

Rituximab, Venetoclax, and Bortezomib for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Who this might be right for
High Grade B-Cell Lymphoma, Not Otherwise SpecifiedRecurrent Burkitt LymphomaRecurrent Diffuse Large B-Cell Lymphoma+4 more
Rutgers, The State University of New Jersey
Early research (Phase 1)Ended earlyNCT00521638
What this trial is testing

Study Evaluating TRU-015 in B-Cell Non-Hodgkin's Lymphoma

Who this might be right for
Lymphoma, B-Cell
Wyeth is now a wholly owned subsidiary of Pfizer 120
Early research (Phase 1)Ended earlyNCT02978235
What this trial is testing

A Dose Finding Study Followed by a Safety and Efficacy Study for Patients With Multiple Myeloma or Lymphoma

Who this might be right for
Multiple MyelomaNonHodgkin Lymphoma
Taiho Oncology, Inc. 11
Testing effectiveness (Phase 2)Active Not RecruitingNCT03162536
What this trial is testing

Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001)

Who this might be right for
Lymphoma, B-CellSmall Lymphocytic LymphomaChronic Lymphocytic Leukemia+6 more
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) 190
Testing effectiveness (Phase 2)Study completedNCT04205409
What this trial is testing

Nivolumab for Relapsed, Refractory, or Detectable Disease Post Chimeric Antigen Receptor T-cell Treatment in Patients With Hematologic Malignancies

Who this might be right for
Recurrent Chronic Lymphocytic LeukemiaRecurrent Diffuse Large B-Cell LymphomaRecurrent Follicular Lymphoma+15 more
University of Washington 20
Very early researchUnknownNCT04028440
What this trial is testing

ΓδT Cells Immunotherapy in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma (NHL)

Who this might be right for
Non-Hodgkin's LymphomaRelapsed or Refractory B Cell Non-Hodgkin's LymphomaChronic Lymphoblastic Leukemia+1 more
Institute of Hematology & Blood Diseases Hospital, China 6
Early research (Phase 1)Active Not RecruitingNCT03479268
What this trial is testing

Pevonedistat and Ibrutinib in Treating Participants With Relapsed or Refractory CLL or Non-Hodgkin Lymphoma

Who this might be right for
B-Cell Prolymphocytic LeukemiaRecurrent Chronic Lymphocytic LeukemiaRecurrent Diffuse Large B-Cell Lymphoma+15 more
City of Hope Medical Center 18
Testing effectiveness (Phase 2)UnknownNCT01016990
What this trial is testing

Valproic Acid in Treating Patients With Previously Treated Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Chronic Lymphocytic Leukemia

Who this might be right for
LeukemiaLymphoma
Auxilio Mutuo Cancer Center 52
Early research (Phase 1)Looking for participantsNCT05098613
What this trial is testing

Preliminary Safety and Tolerability of CD19x22 CAR T Cells in Adolescent and Adult R/R B-NHL Patients

Who this might be right for
Non-Hodgkin LymphomaB-cell Non-Hodgkin Lymphoma (B-NHL)Mantle Cell Lymphoma (MCL)+1 more
University of Colorado, Denver 68
Testing effectiveness (Phase 2)Looking for participantsNCT05326243
What this trial is testing

Phase 1/2 Study of CD19 Chimeric Antigen Receptor T-cell (CD19 CAR-T; PL001) for Relapsed or Refractory B-cell Lymphoma

Who this might be right for
Diffuse Large B Cell LymphomaPrimary Mediastinal Large B Cell LymphomaLarge B-cell Lymphoma+2 more
Pell Bio-Med Technology Co., Ltd. 49
Testing effectiveness (Phase 2)Ended earlyNCT01944943
What this trial is testing

Phase II Study of Vismodegib in Patients With Refractory or Relapsed B-cell Lymphoma or Chronic Lymphocytic Leukemia

Who this might be right for
Diffuse Large B-cell LymphomaIndolent Non-hodgkin LymphomaPrimary Central Nervous System Lymphoma+1 more
The Lymphoma Academic Research Organisation 31
Early research (Phase 1)Looking for participantsNCT06326008
What this trial is testing

Safety, Tolerability, and Pharmacokinetics of Donor-derived CD19 CAR Therapy Bridged Allo-HSCT and Sequential Donor-derived CD22 CAR Therapy for r/r B-ALL: a Clinical Trial

Who this might be right for
B-cell Acute Lymphoblastic LeukemiaAcute Lymphoblastic Leukemia, in Relapse
Beijing GoBroad Hospital 48
Testing effectiveness (Phase 2)Ended earlyNCT02413489
What this trial is testing

An Efficacy and Safety Proof of Concept Study of Daratumumab in Relapsed/Refractory Mantle Cell Lymphoma, Diffuse Large B-Cell Lymphoma, and Follicular Lymphoma

Who this might be right for
Lymphoma, Mantle-CellLymphoma, Large B-Cell, DiffuseLymphoma, Follicular
Janssen Research & Development, LLC 36
Early research (Phase 1)Study completedNCT03939026
What this trial is testing

Safety and Efficacy of ALLO-501 Anti-CD19 Allogeneic CAR T Cells in Adults With Relapsed/Refractory Large B Cell or Follicular Lymphoma

Who this might be right for
Relapsed/Refractory Large B Cell LymphomaRelapsed/Refractory Follicular Lymphoma
Allogene Therapeutics 50
Testing effectiveness (Phase 2)Ended earlyNCT05588440
What this trial is testing

A Clinical Study of ONCT-808 in Subjects With Relapsed or Refractory B-Cell Malignancies

Who this might be right for
Relapsed/Refractory Aggressive B-Cell Malignancies
Oncternal Therapeutics, Inc 9
Testing effectiveness (Phase 2)Looking for participantsNCT06526793
What this trial is testing

Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL

Who this might be right for
B-cell Non-Hodgkin LymphomaFollicular Lymphoma (FL)Large B-Cell Lymphoma (LBCL)
AstraZeneca 270
Next Page